1984 Volume 32 Issue Supplement4 Pages 316-322
Fundamental and clinical studies were carried out on Sulbactam/Cefoperazone (SBT/CPZ), new injectable antibiotics composed of a mixture of Cefoperazone (CPZ) and Sulbactam, a new 13-lactamase inhibitor, equally. And the following results were obtained.
1) Antimicrobial activities of SBT/CPZ against CPZ resistant E. coli and Indole positive proteus were superior to those of CPZ alone. But there was no combination effect on MICs for S. aureus
In Klebsiella spp., S. marcescens, Proteus mirabilis and Pseudomonas spp. only a little improvement of activity was observed, and the lowest MICs against Acinetobacter spp. was observed in SBT alone.
The peak serum concentrations of CPZ and SBT, after a drip infusion of 1.0g of SBT/CPZ for one hour were 112.4μg/ml and 26.3μg/ml respectively. And the proportion of serum levels of SBT and CPZ were 1: 4.3 at the peak, 1: 3.6 at 2 hours and 1: 9.3 at 4 hours after start of infusion. The urinary excretions rate up to 6 hours after start of infusion were 10.3%(CPZ) and 40.7%(SBT) respectively.
A total of 16 patients (14 with respiratory and 2 with urinary tract infections) were treated with 2.0-4.0g daily dose of SBT/CPZ for 2-15 days. Clinical efficacy was evaluated as good in 7, fair in 2, poor in 6 and unassessable in 1. The overall efficacy rate was therefore 46.7%.
No subjective side effect was observed, but in clinicalaboratory data, slight and transient increasings of transaminase and Al-p was observed in 2 patients after the treatments.
